However, a single HER2-targeted agent has shown only modest efficacy in HER2 overexpressing salivary gland carcinoma, prompting interest in combinatorial approaches to overcome the limitation of single-agent approaches [30]. The gene discussed is ERBB2; the disease is salivary gland carcinoma.